Nastassia Samal/iStock via Getty Images
With many biotechs and pharmas needing to fill impending revenue holes coming later in the decade, M&A is posed to pick up, but not until government and regulatory uncertainty settles down.
Dealmaking experts taking part in a panel discussion at